Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
biorxiv(2024)
摘要
Background Immune checkpoint inhibitors (ICIs) and their combination with other therapies such as chemotherapy, fail in most cancer patients. We previously identified the PDZ-LIM domain-containing protein 2 (PDLIM2) as a bona fide tumor suppressor that is repressed in lung cancer to drive cancer and its chemo and immunotherapy resistance, suggesting a new target for lung cancer therapy improvement.
Methods Human clinical samples and data were used to investigate PDLIM2 genetic and epigenetic changes in lung cancer. Using an endogenous mouse lung cancer model faithfully recapitulating refractory human lung cancer and a clinically feasible nano-delivery system, we investigated the therapeutic efficacy, action mechanism, and safety of systemically administrated PDLIM2 expression plasmids encapsulated in nanoparticles (nanoPDLIM2) and its combination with PD-1 antibody and chemotherapeutic drugs.
Results PDLIM2 repression in human lung cancer involves both genetic deletion and epigenetic alteration. NanoPDLIM2 showed low toxicity, high tumor specificity, antitumor activity, and greatly improved the efficacy of anti-PD-1 and chemotherapeutic drugs, with complete tumor remission in most mice and substantial tumor reduction in the remaining mice by their triple combination. Mechanistically, nanoPDLIM2 increased major histocompatibility complex class I (MHC-I) expression, suppressed multi-drug resistance 1 (MDR1) induction and survival genes and other tumor-related genes expression in tumor cells, and enhanced lymphocyte tumor infiltration, turning the cold tumors hot and sensitive to ICIs and rendering them vulnerable to chemotherapeutic drugs and activated tumor-infiltrating lymphocytes (TILs) including those unleashed by ICIs.
Conclusions These studies established a clinically applicable PDLIM2-based combination therapy with great efficacy for lung cancer and possibly other cold cancers.
### Competing Interest Statement
The authors have declared no competing interest.
* AC
: adenocarcinoma
BFA
: brefeldin A
CNV
: copy number variation
CTL
: cytotoxic T lymphocyte
FACS
: fluorescent activated cell sorting
FDA
: Food and Drug Administration
IFNγ
: interferon-γ
ICD
: immunogenic cell death
ICI
: immune checkpoint inhibitor
IHC
: immunohistochemistry
i.p.
: intraperitoneal
i.v.
: intravenous
LOH
: loss of heterozygosity
MDR1
: multi-drug resistance 1
MHC-I
: major histocompatibility complex class I
nanoPDLIM2
: nanoparticle-encapsulated PDLIM2-expression plasmids
NF-κB
: nuclear factor-κB
NIH
: National Institutes of Health
ORR
: objective response rate
OS
: overall survival
PD-1
: programmed cell death 1
PD-L1
: programmed death ligand 1
PD-L2
: programmed death ligand 2
PDLIM2
: PDZ-LIM domain-containing protein 2
PEI
: polyethylenimine
PFS
: progression-free survival
PMA
: phorbol 12-myristate 13-acetate
qPCR
: quantitative polymerase chain reaction
SEM
: standard error of the mean
STAT3
: signal transducer and activator of transcription 3
TCGA
: The Cancer Genome Atlas
TIL
: tumor-infiltrating lymphocyte
WT
: wild type.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要